Daewoong Pharmaceutical Co. LTD.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS7
PHASE 3 / 2-36
RECRUITING0
READOUTS ≤12 MONTHS1
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| DWP712 inj. NCT07013279 |
P3 | Not yet recruiting | Glabellar Lines | 324 | 2025-12-31 |
| DWP16001 0.3mg NCT06606093 |
P3 | Not yet recruiting | Type 2 Diabetic Nephropathy | 348 | 2026-09-01 |
| DWN12088 NCT05389215 |
P2 | Active, not recruiting | Idiopathic Pulmonary Fibrosis | 102 | 2026-10-13 (+29 mo) |
| DWP16001 NCT07619833 |
P3 | Not yet recruiting | T2DM (Type 2 Diabetes Mellitus) | 510 | 2027-11 |
| DWP14012 40mg (Fexuprazan) NCT07730138 |
P3 | Not yet recruiting | Gastric Ulcer | 384 | 2028-04-15 |
| DWP450 20 U NCT07783763 |
P3 | Not yet recruiting | Glabellar Lines | 120 | 2028-05 |
| DWP14012 20mg NCT07746518 |
P3 | Not yet recruiting | Healed Erosive Esophagitis | 420 | 2029-08 |